OBJECTIVE: The prognosis of @entity1149 ( @entity1149 ) with brain metastasis is very poor, with median survival rate below 6 months, even if treated with palliative radio and/or chemotherapy. To assess the effectiveness of surgical treatment for this kind of @entity1 we reviewed our experience. METHODS: From January 1989 to October 1999, 30 @entity1 (26 males and four females; mean age: 58.7 years) with @entity1149 and single brain metastasis underwent surgical treatment of both primary @entity2 and @entity75 . @entity1 (pts) were divided into two major groups. In group 1 (G1) 20 pts (18 males and two females) presented a synchronous brain metastasis. In group 2 (G2) 10 pts (eight males and two females) presented a metachronous brain metastasis during the follow-up period (range 3-24 months since the @entity5 ). @entity1 selected in G1 had T1-2, N0-1 clinical staging, good 'performance status' (ECOG:0--1; Karnofsky index > 70%), age < 75 years. Craniotomy has always been the first approach. In G2 also @entity1 with locally advanced @entity5 (T3 and/or N2) were included. Whole brain radiotherapy and/or chemotherapy was the post-operative choice treatment. RESULTS: Histologic findings have shown: @entity420 in 17 cases (12 in G1; five in G2), @entity957 in 10 cases (six in G1; four in G2), @entity152 in 2 (one in G1; one in G2) and @entity152 in one (G1). Survival analysis (Kaplan--Meier method) has shown an overall value of 80% at 1 year (95% in G1; 50% in G2), 41% at 2 years (47% in G1; 30% in G2) and 17% at 3 years (14% in G1; 20% in G2). Overall median survival @entity4318 months (23 in G1; 11 in G2); mean survival 27.8 months (30.3 months in G1; 22.8 months in G2). According to univariate analysis prognosis is definitively better in N0 @entity5 compared to N1-2 @entity5 and in @entity420 cases compared to other histotypes (P < 0.05). CONCLUSIONS: We can conclude that combined surgical therapy is, nowadays, the choice treatment for this kind of @entity1 , even though restricted to selected cases. The knowledge of prognostic factors may optimize indications for surgery.

XXXX with single brain metastasis: the role of surgical treatment.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4318 :: ('MESH:C038399', 'Chemical') :: ['is 23'] @entity75 :: ('MESH:D001927', 'Disease') :: ['secondary cerebral lesion'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor', 'tumors'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity152 :: ('MESH:D018287', 'Disease') :: ['large cell neuroendocrine carcinoma', 'large cell carcinoma'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity1149 :: (MESH:D002289,Disease) :: ['Non-small cell lung cancer']
